Translation Considerations for Hyperthermic Intraperitoneal Chemotherapy

Current Problems in Cancer

Volumn 33, Issue 3, 2009, Pages 194-202

  Stewart IV, John H ^a   Shen, Perry ^a   Levine, Edward A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; MITOMYCIN C; OXALIPLATIN; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; NONHUMAN; ONCOLOGY; PERITONEUM CANCER; SURGICAL TECHNIQUE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERTHERMIA, INDUCED; PERITONEAL NEOPLASMS; PROTEIN BIOSYNTHESIS;

EID: 67651245346     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2009.06.006     Document Type: Article

References (24)

1. Meyers M.A. Distribution of intra-abdominal malignant seeding: Dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med 119 (1973) 198-206
2. Carmignani C.P., Sugarbaker T.A., Bromley C.M., and Sugarbaker P.H. Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread. Cancer Metastasis Rev 22 (2003) 465-472
3. Averbach A.M., Jacquet P., and Sugarbaker P.H. Surgical technique and colorectal cancer: Impaction on local recurrence and survival. Tumori 81 3 (1995) 65-71 (suppl)
4. Eggermont A.M., Steller E.P., and Sugarbaker P.H. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 102 (1987) 71-78
5. Dedrick R.L., and Flessner M.F. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 89 (1997) 480-487
6. Dedrick R.L. Interspecies scaling of regional drug delivery. J Pharmacol Sci 75 (1986) 1047-1052
7. Flessner M.F., Fenstermacher J.D., Dedrick R.L., and Blasberg R.G. A distributed model of peritoneal-plasma transport: Tissue concentration gradients. Am J Physiol 248 3 (1985) F425-F435
8. Kuzuya T., Yamauchi M., Ito A., Hasegawa M., Hasegawa T., and Nabeshima T. Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy. J Pharm Pharmacol 46 (1994) 685-689
9. Speyer J.L., Collins J.M., Dedrick R.L., Brennan M.F., Buckpitt A.R., Londer H., et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40 (1980) 567-572
10. Israel V.K., Jiang C., Muggia F.M., Tulpule A., Jeffers S., Leichman L., et al. Intraperitoneal 5-fluoro-2′-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: A pharmacokinetic and toxicity study. Cancer Chemother Pharmacol 37 1-2 (1995) 32-38
11. Ozols R.F., Young R.C., Speyer J.L., Sugarbaker P.H., Greene R., Jenkins J., et al. Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42 (1982) 4265-4269
12. Bartlett D.L., Buell J.F., Libutti S.K., Reed E., Lee K.B., Figg W.D., et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer 83 (1998) 1251-1261
13. Markman M., Brady M.F., Spirtos N.M., Hanjani P., and Rubin S.C. Phase ii trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group study. J Clin Oncol 16 (1998) 2620-2624
14. Stewart J.H., Shen P., Russell G., Fenstermaker J., Mcwilliams L., Coldrun F.M., et al. A phase Ii trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol 15 (2008) 2137-2145
15. Elias D., Bonnay M., Puizillou J.M., Antoun S., Demirdjian S., El O.A., et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: Pharmacokinetics and tissue distribution. Ann Oncol 13 (2002) 267-272
16. Barlogie B., Corry P.M., and Drewinko B. In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C. Cancer Res 40 (1980) 1165-1168
17. El Kareh A.W., and Secomb T.W. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia 6 (2004) 117-127
18. Roti Roti J.L. Cellular responses to hyperthermia (40-46°C): Cell killing and molecular events. Int J Hyperthermia 24 (2008) 3-15
19. Lepock J.R. How do cells respond to their thermal environment?. Int J Hyperthermia 21 (2005) 681-687
20. Walther W., Arlt F., Fichtner I., Aumann J., Stein U., and Schlag P.M. Heat-inducible in vivo gene therapy of colon carcinoma by human mdr1 promoter-regulated tumor necrosis factor-alpha expression. Mol Cancer Ther 6 (2007) 236-243
21. Schett G., Steiner C.W., Xu Q., Smolen J.S., and Steiner G. TNFalpha mediates susceptibility to heat-induced apoptosis by protein phosphatase-mediated inhibition of the HSF1/hsp70 stress response. Cell Death Differ 10 (2003) 1126-1136
22. Rossi A., Ciafre S., Balsamo M., Pierimarchi P., and Santoro M.G. Targeting the heat shock factor 1 by RNA interference: A potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer. Cancer Res 66 (2006) 7678-7685
23. Tu S., Mcstay G.P., Boucher L.M., Mak T., Beere H.M., and Green D.R. In situ trapping of activated initiator caspases reveals a role for caspase-2 in heat shock-induced apoptosis. Nat Cell Biol 8 (2006) 72-77
24. Pagliari L.J., Kuwana T., Bonzon C., Newmeyer D.D., Tu S., Beere H.M., et al. The multidomain proapoptotic molecules Bax and Bak are directly activated by heat. Proc Natl Acad Sci U S A 102 (2005) 17975-17980